Drug Trial Radar · NCT02775916
Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
Last checked: Nov 20, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jun 1, 2016
Primary completion
May 17, 2017
Study completion May 17, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 18, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173 in patients with primary Sjögren's syndrome.
Conditions
- Primary Sjögren's Syndrome
Interventions
CDZ173Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Primary Sjögren's Syndrome With Adverse Events and Death up to Day 85Time frame: up to Day 85
- Change From Baseline in the EULAR Sjögren's Syndrome Patient Reported Intensity (ESSPRI) After 12 Weeks of Treatment Day 85Time frame: Baseline and 12 weeks (Day 85)
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Debrecen, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.